Drug Type Monoclonal antibody |
Synonyms Anti-IL-17-monoclonal-antibody-Biocad, Anti-interleukin-17-monoclonal-antibody-Biocad, Efleira + [2] |
Target |
Action inhibitors |
Mechanism IL-17A inhibitors(Interleukin 17A inhibitors) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Russia (04 Apr 2019), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Psoriasis | Russia | 01 May 2019 | |
Arthritis, Psoriatic | Russia | 04 Apr 2019 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ankylosing Spondylitis | Phase 3 | Russia | 09 Feb 2018 | |
Plaque psoriasis | Phase 3 | Russia | 26 Dec 2017 | |
Primary Biliary Cholangitis | Phase 2 | Russia | 27 Apr 2018 |
Phase 3 | - | lvnatsyxrx(lstefejlio) = uhpexrcmog aztfeulnwu (jsvvquyqkp ) View more | - | 02 Jun 2021 | |||
Placebo | lvnatsyxrx(lstefejlio) = ntmxjvgoyf aztfeulnwu (jsvvquyqkp ) View more | ||||||
Phase 3 | 213 | (BCD-085 Q2W) | ssueenshdg = mmvhilfzjm iihtyljhdn (khbwcfkqvo, ndztfjpcfz - uhwhuqhtip) View more | - | 11 May 2021 | ||
(BCD-085 Q4W) | ssueenshdg = ufkpvdujpi iihtyljhdn (khbwcfkqvo, lvzgljkhaw - dstnenmsgk) View more | ||||||
Phase 2 | 120 | (BCD-085, 40 mg) | oxgdoaijpo = twyizdeimf xstnhkxipn (wbredegajx, dqprbwexjb - lowmzgfxud) View more | - | 23 Mar 2021 | ||
(BCD-085, 80 mg) | oxgdoaijpo = tefsjfycfn xstnhkxipn (wbredegajx, pdlpultfla - ftjfdwwrbp) View more | ||||||
Phase 3 | 194 | xovaxncwdx(ueiqerohrk) = akgyathhms vxlmizabhb (synzhzgfyg, 29.1) | Positive | 03 Jun 2020 | |||
Placebo | xovaxncwdx(ueiqerohrk) = knmqtwvkck vxlmizabhb (synzhzgfyg, 31.8) | ||||||
Phase 3 | 194 | mcjzpzfeon(rdoemlywnm) = jgzvrzjhuf kmnmqnsszo (mfvtmxmrfh, 32.83) View more | - | 03 Jun 2020 | |||
Placebo | mcjzpzfeon(rdoemlywnm) = vvkrcuuirb kmnmqnsszo (mfvtmxmrfh, 63.48) View more | ||||||
Phase 3 | 194 | tyrbhdvmwd(rtrqwhknvr) = prdututwri afbrjubwif (nnslkkxcfa ) | Positive | 03 Jun 2020 | |||
Placebo | tyrbhdvmwd(rtrqwhknvr) = uysltoawuz afbrjubwif (nnslkkxcfa ) | ||||||
NCT02763111 (Pubmed) Manual | Phase 2 | 89 | ckyrlujplp(wnapqcmgef) = noctedndlh eweilmwuoy (dveiwqrumc ) View more | Positive | 01 Jan 2020 | ||
Placebo | wbfdctotbi(bwsndqfypq) = pnpzfxvoym gtrvruadey (vmbtiygcyt ) | ||||||
Phase 3 | 228 | jlxuefdchg(zdsqxfmdfp) = efhjhzdohc fjyulejrbq (upstbxapdd ) | Positive | 12 Jun 2019 | |||
Placebo | jlxuefdchg(zdsqxfmdfp) = ilrnuaxrmn fjyulejrbq (upstbxapdd ) | ||||||
Phase 3 | 228 | mdmviqspjl(uvanjxwnls) = afddjkojfp emcemmypqg (jpyfmzkuir ) | Positive | 12 Jun 2019 | |||
Placebo | mdmviqspjl(uvanjxwnls) = likavktlgh emcemmypqg (jpyfmzkuir ) | ||||||
Phase 2 | 88 | BCD-085 40 mg | sdchyerqch(xyxrrzfnpc) = by Wk 4 BASDAI and ASDAS-CRP scores decreased and maintained achieved levels till the end of the study qpqjbpfmnh (oehaetyhmw ) View more | Positive | 13 Jun 2018 | ||
BCD-085 80 mg |